PT2827900T - Dispersões sólidas amorfas para utilização no tratamento de cancro cerebral - Google Patents

Dispersões sólidas amorfas para utilização no tratamento de cancro cerebral

Info

Publication number
PT2827900T
PT2827900T PT137144978T PT13714497T PT2827900T PT 2827900 T PT2827900 T PT 2827900T PT 137144978 T PT137144978 T PT 137144978T PT 13714497 T PT13714497 T PT 13714497T PT 2827900 T PT2827900 T PT 2827900T
Authority
PT
Portugal
Prior art keywords
treatment
solid dispersion
amorphous solid
brain cancer
brain
Prior art date
Application number
PT137144978T
Other languages
English (en)
Inventor
L Winski Shannon
A Lee Patrice
Koch Kevin
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2827900(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of PT2827900T publication Critical patent/PT2827900T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
PT137144978T 2012-03-23 2013-03-25 Dispersões sólidas amorfas para utilização no tratamento de cancro cerebral PT2827900T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23

Publications (1)

Publication Number Publication Date
PT2827900T true PT2827900T (pt) 2018-06-14

Family

ID=48048296

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181629718T PT3400943T (pt) 2012-03-23 2013-03-25 Compostos para serem utilizados no tratamendo de metástase no cérebro num doente com cancro da mama positivo para erbb2.
PT137144978T PT2827900T (pt) 2012-03-23 2013-03-25 Dispersões sólidas amorfas para utilização no tratamento de cancro cerebral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT181629718T PT3400943T (pt) 2012-03-23 2013-03-25 Compostos para serem utilizados no tratamendo de metástase no cérebro num doente com cancro da mama positivo para erbb2.

Country Status (30)

Country Link
US (3) US20150110780A1 (pt)
EP (4) EP3400943B1 (pt)
JP (6) JP2015514075A (pt)
KR (3) KR102317166B1 (pt)
CN (2) CN104203279B (pt)
AU (4) AU2013234921A1 (pt)
CA (1) CA2867723C (pt)
CL (1) CL2014002497A1 (pt)
CO (1) CO7071139A2 (pt)
CY (2) CY1120204T1 (pt)
DK (2) DK2827900T3 (pt)
ES (2) ES2855142T3 (pt)
HK (1) HK1206276A1 (pt)
HR (1) HRP20180659T1 (pt)
HU (2) HUE053156T2 (pt)
IL (3) IL234627B (pt)
LT (1) LT2827900T (pt)
MX (1) MX354024B (pt)
MY (2) MY174883A (pt)
NZ (4) NZ756264A (pt)
PH (1) PH12014502032A1 (pt)
PL (2) PL3400943T3 (pt)
PT (2) PT3400943T (pt)
RS (1) RS57140B1 (pt)
RU (2) RU2672575C2 (pt)
SG (1) SG11201405954YA (pt)
SI (2) SI2827900T1 (pt)
TR (1) TR201808450T4 (pt)
UA (1) UA122044C2 (pt)
WO (1) WO2013142875A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035247T2 (hu) 2011-10-14 2018-05-02 Array Biopharma Inc Szilárd diszperzió
EP2766363A1 (en) 2011-10-14 2014-08-20 Array Biopharma, Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
ES2855142T3 (es) 2012-03-23 2021-09-23 Array Biopharma Inc Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+
CA3055957A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
WO2019197973A1 (en) * 2018-04-09 2019-10-17 Moshe Giladi Treating tumors with ttfields and an aurora kinase inhibitor
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
PL4084778T3 (pl) 2019-12-30 2024-03-04 Deciphera Pharmaceuticals, Llc Formulacje amorficznych inhibitorów kinazy i sposoby ich zastosowania

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
CN103772373B (zh) 2003-08-14 2017-06-09 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
BR122018075851B1 (pt) 2005-11-15 2022-01-11 Array Biopharma Inc Compostos relacionados ao tratamento de doença hiperproliferativa e processos para preparar compostos
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
EP2766363A1 (en) 2011-10-14 2014-08-20 Array Biopharma, Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
HUE035247T2 (hu) 2011-10-14 2018-05-02 Array Biopharma Inc Szilárd diszperzió
ES2855142T3 (es) 2012-03-23 2021-09-23 Array Biopharma Inc Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+

Also Published As

Publication number Publication date
ES2673165T3 (es) 2018-06-20
DK2827900T3 (en) 2018-05-07
IL261659A (en) 2018-10-31
KR102490961B1 (ko) 2023-01-19
MY174883A (en) 2020-05-20
HK1206276A1 (en) 2016-01-08
PL2827900T3 (pl) 2018-08-31
NZ630843A (en) 2017-01-27
NZ756264A (en) 2022-09-30
JP2017141302A (ja) 2017-08-17
DK3400943T3 (da) 2021-02-08
WO2013142875A1 (en) 2013-09-26
IL269205B (en) 2020-06-30
HUE053156T2 (hu) 2021-06-28
CA2867723C (en) 2022-11-08
EP4252855A3 (en) 2023-11-15
KR20140139009A (ko) 2014-12-04
EP2827900A1 (en) 2015-01-28
JP2015514075A (ja) 2015-05-18
JP2024019526A (ja) 2024-02-09
IL234627B (en) 2018-10-31
TR201808450T4 (tr) 2018-07-23
PT3400943T (pt) 2021-02-02
JP2019081792A (ja) 2019-05-30
PH12014502032A1 (en) 2014-11-24
HUE037966T2 (hu) 2018-09-28
JP2022190126A (ja) 2022-12-22
KR102317166B1 (ko) 2021-10-26
JP2021178820A (ja) 2021-11-18
KR20210131426A (ko) 2021-11-02
RU2014142700A (ru) 2016-05-20
EP4252855A2 (en) 2023-10-04
AU2021261849A1 (en) 2021-12-02
SI3400943T1 (sl) 2021-03-31
JP7404485B2 (ja) 2023-12-25
CY1120204T1 (el) 2018-12-12
RU2018138976A3 (pt) 2022-04-08
LT2827900T (lt) 2018-05-10
PL3400943T3 (pl) 2021-06-14
CA2867723A1 (en) 2013-09-26
EP3400943A1 (en) 2018-11-14
SG11201405954YA (en) 2014-10-30
CN104203279A (zh) 2014-12-10
MX354024B (es) 2018-02-08
CN109223791A (zh) 2019-01-18
CL2014002497A1 (es) 2014-11-14
AU2017272232A1 (en) 2018-01-04
US20230190749A1 (en) 2023-06-22
KR20200115656A (ko) 2020-10-07
KR102160462B1 (ko) 2020-09-28
UA122044C2 (uk) 2020-09-10
NZ741615A (en) 2019-10-25
US20150110780A1 (en) 2015-04-23
CY1123837T1 (el) 2022-05-27
MY202114A (en) 2024-04-04
CO7071139A2 (es) 2014-09-30
AU2013234921A1 (en) 2014-10-02
RU2018138976A (ru) 2018-12-06
ES2855142T3 (es) 2021-09-23
AU2017272232C1 (en) 2019-08-15
EP3842044A1 (en) 2021-06-30
US20190255051A1 (en) 2019-08-22
HRP20180659T1 (hr) 2018-06-01
AU2017272232B2 (en) 2019-02-28
US11504370B2 (en) 2022-11-22
EP3400943B1 (en) 2020-12-02
AU2019203618B2 (en) 2021-08-05
RS57140B1 (sr) 2018-07-31
MX2014011437A (es) 2014-11-10
NZ724544A (en) 2018-05-25
AU2019203618A1 (en) 2019-06-13
EP2827900B1 (en) 2018-03-21
JP6898960B2 (ja) 2021-07-07
CN104203279B (zh) 2018-10-30
IL269205A (en) 2019-11-28
RU2672575C2 (ru) 2018-11-16
SI2827900T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
HRP20180659T1 (hr) Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1209745A1 (en) Compounds and methods for antiviral treatment
EP2819703A4 (en) TREATMENT OF PAIN
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL238116B (en) A process for preparing compounds for use in the treatment of cancer
ZA201408855B (en) Flocculation treatment agent
HK1212340A1 (en) Substituted indazol pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
IL239374A0 (en) Preparations and methods for treating brain tumors
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
GB201221123D0 (en) Device for photodynamic treatment
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
ZA201407164B (en) Device for use in the treatment hyperbilirubinemia